A detailed history of Geode Capital Management, LLC transactions in Compugen LTD stock. As of the latest transaction made, Geode Capital Management, LLC holds 50,395 shares of CGEN stock, worth $82,647. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,395
Previous 50,395 -0.0%
Holding current value
$82,647
Previous $130,000 35.38%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.75 - $2.95 $17,178 - $28,957
9,816 Added 24.19%
50,395 $130,000
Q2 2023

Aug 11, 2023

BUY
$0.57 - $1.38 $7,643 - $18,504
13,409 Added 49.35%
40,579 $46,000
Q2 2022

Aug 12, 2022

SELL
$1.57 - $3.33 $58,314 - $123,686
-37,143 Reduced 57.75%
27,170 $50,000
Q4 2021

Feb 11, 2022

SELL
$4.09 - $7.16 $386,222 - $676,125
-94,431 Reduced 59.49%
64,313 $276,000
Q3 2021

Nov 12, 2021

BUY
$5.8 - $8.02 $368,149 - $509,061
63,474 Added 66.63%
158,744 $947,000
Q2 2021

Aug 13, 2021

BUY
$6.87 - $9.16 $183,442 - $244,590
26,702 Added 38.94%
95,270 $788,000
Q1 2021

May 12, 2021

BUY
$7.67 - $13.77 $82,437 - $147,999
10,748 Added 18.59%
68,568 $588,000
Q4 2020

Feb 12, 2021

SELL
$12.07 - $17.95 $267,278 - $397,484
-22,144 Reduced 27.69%
57,820 $700,000
Q3 2020

Nov 13, 2020

BUY
$14.16 - $19.45 $334,303 - $459,195
23,609 Added 41.89%
79,964 $1.3 Million
Q2 2020

Aug 13, 2020

BUY
$6.97 - $17.12 $135,915 - $333,840
19,500 Added 52.91%
56,355 $846,000
Q1 2020

May 14, 2020

SELL
$5.79 - $11.83 $42,481 - $86,796
-7,337 Reduced 16.6%
36,855 $267,000
Q2 2019

Aug 14, 2019

BUY
$2.8 - $4.14 $51,937 - $76,792
18,549 Added 72.34%
44,192 $169,000
Q4 2017

Feb 13, 2018

SELL
$2.35 - $4.0 $15,089 - $25,684
-6,421 Reduced 20.03%
25,643 $64,000
Q2 2017

Aug 14, 2017

BUY
N/A
32,064
32,064 $121,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $142M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.